Scholarlink

Objective <p>To evaluate the risk of oral mucositis in cetuximab-plus-radiotherapy compared to cisplatin-plus-radiotherapy in head and neck cancer patients.</p> Materials and methods <p>This PROSPERO-registered systematic review conducted searches through PubMed, Scopus, Web of Science, LILACS, EBSCOhost, LIVIVO, Embase, and Grey literature (Google Scholar) until March 2025. Therefore, 10 articles were included for the evaluation in this systematic review and meta-analysis. Risk of bias (RoB) was assessed by Rob-2, and meta-analysis was performed (combined relative risk) in subgroups. The assessment of the certainty of evidence was analyzed by GRADE-pro.</p> Results <p>From 4118 reviewed articles, 10 RCTs were included in the systematic review and meta-analysis, and 4329 patients were evaluated. The Rob was predominantly low. The relative risk of oral mucositis was 1.15 (95% CI = 1.03 to 1.29) higher in cetuximab-plus-radiotherapy compared with cisplatin-plus-radiotherapy in head and neck cancer patients (<i>p</i> = 0.010). There was no heterogeneity (<i>p</i> = 0.890, <i>I</i><sup>2</sup> = 0%) or Rob’s publication (<i>p</i> = 0.404). The GRADE-pro analysis was moderate.</p> Conclusion <p>Cetuximab plus radiotherapy in head and neck cancer patients increases by 1.15 times the risk of oral mucositis. Clinical trials with preventing strategies for OM in cetuximab-treated patients were necessary.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cetuximab increases the risk of oral mucositis in radiotherapy-treated head and neck cancer compared to cisplatin: a systematic review of randomized controlled clinical trials

  • 期刊论文

  • 发表日期：

    2025年12月19日

查看全文
  • Gabriella Alves Julião Costa,
  • Reverton Soares Ribeiro,
  • Clarice Lioba de Araújo,
  • André Alves Crispim,
  • Cassia Emanuella Nóbrega Malta,
  • Edson Luiz Cetira Filho,
  • Flávio da Silveira Bittencourt,
  • Fabrício Bitu Sousa,
  • Paulo Goberlânio de Barros Silva

摘要

Objective

To evaluate the risk of oral mucositis in cetuximab-plus-radiotherapy compared to cisplatin-plus-radiotherapy in head and neck cancer patients.

Materials and methods

This PROSPERO-registered systematic review conducted searches through PubMed, Scopus, Web of Science, LILACS, EBSCOhost, LIVIVO, Embase, and Grey literature (Google Scholar) until March 2025. Therefore, 10 articles were included for the evaluation in this systematic review and meta-analysis. Risk of bias (RoB) was assessed by Rob-2, and meta-analysis was performed (combined relative risk) in subgroups. The assessment of the certainty of evidence was analyzed by GRADE-pro.

Results

From 4118 reviewed articles, 10 RCTs were included in the systematic review and meta-analysis, and 4329 patients were evaluated. The Rob was predominantly low. The relative risk of oral mucositis was 1.15 (95% CI = 1.03 to 1.29) higher in cetuximab-plus-radiotherapy compared with cisplatin-plus-radiotherapy in head and neck cancer patients (p = 0.010). There was no heterogeneity (p = 0.890, I2 = 0%) or Rob’s publication (p = 0.404). The GRADE-pro analysis was moderate.

Conclusion

Cetuximab plus radiotherapy in head and neck cancer patients increases by 1.15 times the risk of oral mucositis. Clinical trials with preventing strategies for OM in cetuximab-treated patients were necessary.